$GH

CLARK IAN T sold $2.3M of GH (indirect holdings)

CLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.

Original reporting
SEC EDGAR · CLARK IAN T
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 14,180 shares (about $2.25M) at roughly $158.8 to $159.0 per share, with holdings after the sale of 2,975 shares.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it does not introduce new company fundamentals or guidance.

03

What to watch

No 10b5-1 plan is disclosed here, but the article also provides no context on total holdings, prior sale cadence, or whether other insiders are buying or selling around the same period.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, trades dated 2026-08-04

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc., reported by a director.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Clark Ian T sold $2.25M of GH shares via two open-market trades at about $158.9 on 2026-08-04.

Expected impact

Limited near-term impact; any effect is likely transient unless followed by additional insider selling or new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a moderate dollar value, but it does not include new operational, financial, or regulatory information.

Market effects

Minimal; insider selling at one healthcare diagnostics name does not materially change sector expectations.

None indicated.

None indicated.

Counterpoint

The sale may be driven by personal liquidity needs rather than a view on business prospects, especially given the lack of a stated fundamental catalyst in the filing.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an insider director via open-market transactions.

  • CLARK IAN T

    Director who sold 14,180 shares of GH on 2026-08-04, reported on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.